Immediate versus Delayed Wound Closure in Hidradenitis Suppurativa Surgery: A Comparative Outcomes Study

Abstract

Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease affecting approximately 1% of young adults. Severe and refractory disease commonly requires surgical excision of the affected skin. To date, there is no consensus regarding the most appropriate reconstructive algorithm.

Materials and Methods We conducted a retrospective cohort study including all HS patients who underwent surgical excision in the framework of our multidisciplinary clinic. Operative data and postoperative outcome measures were compared between patients who underwent immediate versus delayed reconstruction. Additionally, reconstructive methods were compared and risk factors for adverse postoperative outcome were identified.

Results A total of 103 patients underwent 158 surgeries for HS excision. The overall complication rate was significantly higher in patients who underwent immediate versus delayed wound closure (31 vs. 16%, p = 0.039). Any intervention for wound closure (immediate or delayed) was associated with increased risk of postoperative complications in comparison to secondary healing (33 vs. 4%, p < 0.001). With delayed closure, the average time to wound closure was 85.4 days with secondary healing only and 57 days with negative pressure wound therapy assisted closure.

Conclusion Risk factors for adverse postoperative outcome in HS surgery are multifactorial and involve both timing and method of reconstruction in addition to various patient factors. The findings of this study strengthen the notion that delayed closure of post-HS excision wounds leads to the most uneventful course in regard to postoperative adverse events; however, this may take up to 3 months. Upon deciding on a reconstructive plan, the risk-to-benefit ratio should be assessed individually weighing the pros and cons of immediate closure and delayed secondary intention.

Keywords

hidradenitis suppurativa - immediate repair - secondary intention

• References

• 1 Jemec GBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366 (02) 158-164
• 2 Burney RE. 35-year experience with surgical treatment of hidradenitis suppurativa. World J Surg 2017; 41 (11) 2723-2730
• 3 Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: current and emerging treatments. J Am Acad Dermatol 2020; 82 (05) 1061-1082
• 4 Saunte DML, Jemec GBE. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA 2017; 318 (20) 2019-2032
• 5 Alikhan A, Sayed C, Alavi A. et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations—PART I. Diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol 2019; 81 (01) 76-90
• 6 Tchero H, Herlin C, Bekara F, Fluieraru S, Teot L. Hidradenitis suppurativa: a systematic review and meta-analysis of therapeutic interventions. Indian J Dermatol Venereol Leprol 2019; 85 (03) 248-257
• 7 Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021; 35 (01) 50-61
• 8 Virtanen P, Gommers R, Oliphant TE. et al; SciPy 1.0 Contributors. SciPy 1.0: fundamental algorithms for scientific computing in Python. Nat Methods 2020; 17 (03) 261-272
• 9 Mehdizadeh A, Hazen PG, Bechara FG. et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol 2015; 73 (5, suppl 1): S70-S77
• 10 Taylor EM, Hamaguchi R, Kramer KM, Kimball AB, Orgill DP. Plastic surgical management of hidradenitis suppurativa. Plast Reconstr Surg 2021; 147 (03) 479-491
• 11 Elliott J, Chui K, Rosa N, Reffell L, Jemec B. Hidradenitis suppurativa: a review of post-operative outcomes. J Plast Reconstr Aesthet Surg 2021; 74 (03) 644-710
• 12 Steele AW, Miller NF, Wallace SJ. et al. Hidradenitis suppurativa: a comparison of institutional experience and the tracking operations and outcomes for plastic surgeons registry. Plast Reconstr Surg 2022; 149 (05) 1216-1224
• 13 Melendez Gonzalez MDM, Sayed CJ. Surgery is an essential aspect of managing patients with hidradenitis suppurativa. J Am Acad Dermatol 2020; 83 (03) 979-980
• 14 Kohorst JJ, Baum CL, Otley CC. et al. Patient satisfaction and quality of life following surgery for hidradenitis suppurativa. Dermatol Surg 2017; 43 (01) 125-133
• 15 Falola RA, DeFazio MV, Anghel EL, Mitnick CDB, Attinger CE, Evans KK. What heals hidradenitis suppurativa: surgery, immunosuppression, or both?. Plast Reconstr Surg 2016; 138 (3, suppl): 219S-229S
• 16 Scuderi N, Monfrecola A, Dessy LA, Fabbrocini G, Megna M, Monfrecola G. Medical and surgical treatment of hidradenitis suppurativa: a review. Skin Appendage Disord 2017; 3 (02) 95-110
• 17 Skorochod R, Margulis A, Adler N. Surgical management of hidradenitis suppurativa: factors associated with postoperative complications and disease recurrence. Plast Reconstr Surg Glob Open 2023; 11 (01) e4752